Adagio Medical Holdings (ADGM) EBITDA (2023 - 2026)

Adagio Medical Holdings (ADGM) has 4 years of EBITDA data on file, last reported at -$5.2 million in Q1 2026.

• For the quarter ending Q1 2026, EBITDA rose 29.7% year-over-year to -$5.2 million; the trailing twelve-month figure through Mar 2026 stood at -$19.6 million (up 28.17% YoY), and the FY2025 full-year result was -$21.9 million, up 64.96% from the prior year.
• EBITDA declined to -$5.2 million in Q1 2026, from -$4.0 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of -$4.0 million in Q4 2025 to a low of -$9.1 million in Q3 2023.
• A 4-year average of -$6.1 million and a median of -$5.5 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA surged 51.27% in 2024 and declined 29.29% in 2025, its largest moves.
• Tracing ADGM's EBITDA over 4 years: stood at -$5.3 million in 2023, then advanced by 17.03% to -$4.4 million in 2024, then grew by 10.33% to -$4.0 million in 2025, then plunged by 31.05% to -$5.2 million in 2026.
• Business Quant data shows ADGM's EBITDA at -$5.2 million in Q1 2026, -$4.0 million in Q4 2025, and -$5.7 million in Q3 2025.